BR112013022523A2 - uso de glicopirrolato para o tratamento de taquicardia - Google Patents

uso de glicopirrolato para o tratamento de taquicardia

Info

Publication number
BR112013022523A2
BR112013022523A2 BR112013022523A BR112013022523A BR112013022523A2 BR 112013022523 A2 BR112013022523 A2 BR 112013022523A2 BR 112013022523 A BR112013022523 A BR 112013022523A BR 112013022523 A BR112013022523 A BR 112013022523A BR 112013022523 A2 BR112013022523 A2 BR 112013022523A2
Authority
BR
Brazil
Prior art keywords
glycopyrrolate
tachycardia
treatment
Prior art date
Application number
BR112013022523A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Tansley
Susan Snape
Original Assignee
Sosei R & D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013022523(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103770.2A external-priority patent/GB201103770D0/en
Priority claimed from GBGB1202256.2A external-priority patent/GB201202256D0/en
Application filed by Sosei R & D Ltd filed Critical Sosei R & D Ltd
Publication of BR112013022523A2 publication Critical patent/BR112013022523A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112013022523A 2011-03-04 2012-03-05 uso de glicopirrolato para o tratamento de taquicardia BR112013022523A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1103770.2A GB201103770D0 (en) 2011-03-04 2011-03-04 Novel use
GBGB1202256.2A GB201202256D0 (en) 2012-02-09 2012-02-09 Novel use
PCT/GB2012/050478 WO2012120284A1 (en) 2011-03-04 2012-03-05 Use of glycopyrrolate for treating tachycardia

Publications (1)

Publication Number Publication Date
BR112013022523A2 true BR112013022523A2 (pt) 2016-11-29

Family

ID=45841526

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013022523A BR112013022523A2 (pt) 2011-03-04 2012-03-05 uso de glicopirrolato para o tratamento de taquicardia

Country Status (20)

Country Link
US (2) US20140080890A1 (enExample)
EP (1) EP2680841B2 (enExample)
JP (1) JP6129081B2 (enExample)
KR (1) KR101853997B1 (enExample)
CN (1) CN103501781B (enExample)
AR (1) AR085616A1 (enExample)
AU (1) AU2012226608B2 (enExample)
BR (1) BR112013022523A2 (enExample)
CA (1) CA2828640C (enExample)
CL (1) CL2013002542A1 (enExample)
EA (1) EA025287B1 (enExample)
ES (1) ES2613754T5 (enExample)
GE (1) GEP201706640B (enExample)
IL (1) IL227972A (enExample)
JO (1) JO3510B1 (enExample)
MD (1) MD4369C1 (enExample)
MX (1) MX356025B (enExample)
TW (1) TWI536988B (enExample)
WO (1) WO2012120284A1 (enExample)
ZA (1) ZA201306130B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3106149T1 (sl) 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
AU2013100009B4 (en) * 2013-01-04 2013-03-14 Novartis Ag Treatment of chronic obstructive pulmonary disease
HK1219059A1 (zh) 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统
SG11201700536XA (en) * 2014-09-09 2017-02-27 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
BR112017009315A2 (pt) * 2014-11-05 2017-12-19 Glenmark Pharmaceuticals Ltd composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios.
SI3346990T1 (sl) 2015-09-09 2020-07-31 Vectura Limited Postopek mletja s curkom
EP3248646B1 (de) * 2016-05-25 2021-02-17 Claudia Mattern Zweiteiliges kunststoffrohling-set
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
WO2018167180A1 (en) * 2017-03-15 2018-09-20 Vectura Limited Method and formulation
KR102669919B1 (ko) * 2019-07-10 2024-05-28 한미약품 주식회사 흡입용 캡슐제 및 이의 제조방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
BE718438A (enExample) * 1967-08-23 1968-12-31
NL8104929A (nl) * 1980-11-12 1982-06-01 Alza Corp Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan.
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP0909163A4 (en) * 1996-07-01 1999-06-09 Sepracor Inc METHOD AND MEANS FOR TREATING URINE INCONTINENCE USING THE (S, R) -GLYCOPYRROLATE ENANTIOMER MAINLY
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
KR20000013487A (ko) * 1998-08-10 2000-03-06 정주영 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물
CA2347856C (en) 1998-11-13 2009-02-17 Jagotec Ag Dry powder for inhalation
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE10136404A1 (de) * 2001-07-26 2003-02-20 Johannes Wohlrab Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
EP1718336B1 (en) 2004-02-06 2008-06-25 MEDA Pharma GmbH & Co. KG Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
US7923455B2 (en) 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
GB0703999D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
WO2010144628A2 (en) 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration

Also Published As

Publication number Publication date
KR101853997B1 (ko) 2018-05-02
ES2613754T3 (es) 2017-05-25
MD20130069A2 (ro) 2014-03-31
AU2012226608B2 (en) 2015-11-26
IL227972A (en) 2017-06-29
CA2828640A1 (en) 2012-09-13
CN103501781A (zh) 2014-01-08
JP2014514271A (ja) 2014-06-19
EP2680841B1 (en) 2016-12-28
US10695321B2 (en) 2020-06-30
KR20140020950A (ko) 2014-02-19
CA2828640C (en) 2017-01-03
MX2013009838A (es) 2016-09-27
AU2012226608A1 (en) 2013-09-12
TWI536988B (zh) 2016-06-11
TW201247198A (en) 2012-12-01
MX356025B (es) 2018-05-09
ES2613754T5 (en) 2026-01-22
NZ614603A (en) 2016-01-29
EA025287B1 (ru) 2016-12-30
MD4369C1 (ro) 2016-04-30
MD4369B1 (ro) 2015-09-30
EP2680841B2 (en) 2025-10-22
IL227972A0 (en) 2013-09-30
CN103501781B (zh) 2016-10-26
CL2013002542A1 (es) 2014-07-11
ZA201306130B (en) 2014-04-30
AR085616A1 (es) 2013-10-16
EP2680841A1 (en) 2014-01-08
US20140080890A1 (en) 2014-03-20
EA201391275A1 (ru) 2014-02-28
WO2012120284A1 (en) 2012-09-13
JO3510B1 (ar) 2020-07-05
US20160143880A1 (en) 2016-05-26
GEP201706640B (en) 2017-03-27
JP6129081B2 (ja) 2017-05-17

Similar Documents

Publication Publication Date Title
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
PT3181119T (pt) Composições de alcano semiflourado para utilização no tratamento de queratoconjuntivite seca
BR112014000033A2 (pt) compostos para o tratamento de dependência química
PT2898885T (pt) Derivados de pirrolopirimidina para utilização no tratamento de infeções virais
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
PT2766039T (pt) Composições para o tratamento de artrite reumatoide e métodos de uso das mesmas
CO7061071A2 (es) Procesos para la preparación de (s)-1-(3-etoxi-4-metoxifenil)-2-metansulfoniletilamina
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
BR112015001712A2 (pt) uso de s-pindolol para o tratamento da caquexia e sarcopenia
CR20140119A (es) Composición y apósito para tratamiento de heridas
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
PT2709604T (pt) Canabidivarina para utilização no tratamento de dor neuropática
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
HRP20182046T1 (hr) Uređaj za kuhanje i postupak njegove upotrebe
CO6890100A2 (es) Tratamientos de combinación para hepatitis c
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
BR112015006512A2 (pt) composição para tratar tecidos biológicos danificados
SMT201500057B (it) Uso della biotina per il trattamento della sclerosi multipla
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BR112015002464A2 (pt) processo para a preparação de carbamat-benzoxazinonas, carbamat-benzoxazinonas e utilização das carbamat-benzoxazinonas
IL227732A0 (en) Cosmetic use
BR112014009456A2 (pt) uso de melatonina para o tratamento e/ou prevenção de mucosite
CO7020857A2 (es) Procedimiento para la preparación de complejos de 68ga

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES GB 1103770.2 E GB 1202256.2, DE 04/03/2011 E 09/02/2012 RESPECTIVAMENTE, REIVINDICADAS NO PCT/GB2012/050478, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTAS PERDAS SE DERAM PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("SOSEI RANDD LTD") SER DISTINTO DAQUELES QUE DEPOSITARAM AS PRIORIDADES REIVINDICADAS E NAO FORAM APRESENTADOS OS DOCUMENTOS COMPROBATORIOS DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: SOSEI R AND D LTD (GB)

B25A Requested transfer of rights approved

Owner name: HEPTARES THERAPEUTICS LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NXERA PHARMA UK LIMITED (GB)